Literature DB >> 761443

Binding of imipramine to plasma proteins: effect of hyperlipoproteinemia.

A Danon, Z Chen.   

Abstract

The binding of imipramine to plasma proteins was studied by equilibrium gel filtration. Imipramine was highly bound to lipoproteins as well as to other plasma proteins. The binding to the lipoproteins was higher in hyperlipoproteinemic patients than in normal subjects and correlated well with both plasma cholesterol and triglyceride levels. The overall percent binding of imipramine was also higher in hyperlipoproteinemic patients than in normal subjects. It is concluded that the varying degree of binding of imipramine to plasma proteins as a result of varying lipoprotein concentrations, as well as the special nature of the binding to lipoproteins, may be of kinetic and possibly clinical significance in hyperlipoproteinemic individuals.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 761443     DOI: 10.1002/cpt1979253316

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  13 in total

Review 1.  Methods of determining plasma and tissue binding of drugs. Pharmacokinetic consequences.

Authors:  G M Pacifici; A Viani
Journal:  Clin Pharmacokinet       Date:  1992-12       Impact factor: 6.447

Review 2.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

3.  Interindividual differences in the binding of antidepressives to plasma proteins: the role of the variants of alpha 1-acid glycoprotein.

Authors:  D Tinguely; P Baumann; M Conti; M Jonzier-Perey; J Schöpf
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 4.  Disease-induced changes in the plasma binding of basic drugs.

Authors:  K M Piafsky
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

Review 5.  Pharmacokinetic optimisation of tricyclic antidepressant therapy.

Authors:  M Furlanut; P Benetello; E Spina
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

6.  Plasma protein binding of imipramine in patients with rheumatoid arthritis.

Authors:  C B Kristensen
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

7.  Effects of hyperlipidemia on the pharmacokinetics of nifedipine in the rat.

Authors:  L A Eliot; R T Foster; F Jamali
Journal:  Pharm Res       Date:  1999-02       Impact factor: 4.200

8.  Lack of accumulation of midazolam in plasma and lipoprotein fractions during intravenous lipid infusions in patients on artificial respiration.

Authors:  I Walter-Sack; J X de Vries; J Rudi; R Conradi; M Kohlmeier; B Kohl; E Weber
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

9.  Binding of amitriptyline and nortriptyline in plasma determined from their equilibrium distributions between red cells and plasma, and between red cells and buffer solution.

Authors:  J E Burch; S G Roberts; M A Raddats
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

Review 10.  Clinical pharmacokinetics of drugs used to treat urge incontinence.

Authors:  David R P Guay
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.